- Johnson & Johnson reported operational sales growth: Innovative Medicines +6.8% led by oncology (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE), TREMFYA, SPRAVATO, CAPLYTA; MedTech +3.6%.
- JNJ Q reports: medical devices missed estimates, weakness in cardiovascular unit; surgical, vision and orthopedics showed strength. Traders note cardio and ortho results may affect peers.
- Johnson & Johnson declared a Q3 2026 cash dividend of $1.34 per common share, payable on September 8, 2026, to shareholders of record as of August 25, 2026; the ex-dividend date is August 25, 2026.
TradingView
Key facts: J&J sales rise; devices miss forecasts; $1.34 dividend
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NYSE:JNJ
- Language
- English (India)
Johnson & Johnson reported operational sales growth: Innovative Medicines +6.8% led by oncology (DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE), TREMFYA, SPRAVATO, CAPLYTA; MedT